NHS-IL2 (selectikine, EMD 521873, MSB0010445) is a novel immunocytokine comprising a human tumor necrosis-targeting antibody (NHS76) that binds to exposed DNA in necrotic regions of tumors, fused to genetically modified IL-2 designed to decrease vascular toxicity by signaling through the high-affinity IL-2 receptor [10,11]. The gene discussed is IL2; the disease is neoplasm.